Methods and apparatus for enhancing a response to nucleic acid vaccines

• US 20040001809A1
• Filed: 06/26/2002
• Published: 01/01/2004
• Est. Priority Date: 06/26/2002
• Status: Abandoned Application

• Current Assignee: PharmaSonics, Inc.
• Original Assignee: PharmaSonics, Inc.
• Inventors: Brisken, Axel F., Zuk, Robert
• Application Number:
  US10/184,143
• Publication Number:
  US 20040001809A1
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61N 2007/0078 with multiple treatment transducers
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092
• CPC Class Codes: C12M 35/04 Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The immune response achieved by the administration of nucleic acid vaccines is enhanced by the application of vibrational energy to the inoculated tissue region. The vibrational energy is selected to enhance transfection of the tissue without substantial tissue damage, relying on a mechanical effect of the vibrational energy. Additionally, vibrational energy intended to mechanically injure the tissue via a thermal effect may also be applied.

Claims

1. A method for enhancing an immune response in an animal, said method comprising:

introducing nucleic acids encoding one or more immunogens to a target site in tissue; and

applying vibrational energy to the target site under at least two different conditions selected to enhance transfection or to produce an inflammatory response.

2. The method of claim 1, wherein applying comprises applying to at least a portion of the target site vibrational energy under first conditions selected to enhance transfection of cells to produce antigen without significant tissue damage.

3. The method of claim 2, wherein applying further comprises applying to at least a portion of the target site vibrational energy under second conditions selected to produce tissue damage to stimulate an inflammatory response to the antigen produced by the transfected cells.

4. The method of claims 1, 2, or 3, wherein said animal is a human.

5. The method of claims 1, 2, or 3, wherein said nucleic acids encode an immunogen which is a protein or peptide of a pathogen.

6. The method of claim 5, wherein said pathogen is selected from the group consisting of a bacterium, a fungus, a yeast, a protozoan, and a virus.

7. The method of claim 6, wherein said pathogen is a bacterium selected from the group consisting of an enteric bacterium, Clostridium, Vibrio, Nocardia, Corynebacterium, Listeria, Legionella, Bacilli, Staphylococcus, Streptococci, Borrelia, Mycobacterium, Neisserium and Trepanema bacterium.

8. The method of claim 6, wherein said pathogen is a fungus selected from the group consisting of Dermatophyte, Pneumocystis, Trypanosoma, Plasmodium, Candida, Cryptococcus, Histoplasma, Coccidioide, an Amoeba and Schistosome.

9. The method of claim 6, wherein said pathogen is a virus selected from the group consisting of parvovirus, an orthomyxovirus, paramyxovirus, and picomavirus, papovirus, herpesvirus, togavirus, and retrovirus.

10. The method of claim 9, wherein said pathogen is the retrovirus HIV.

11. The method of claim 10, wherein the nucleic acid vaccine encodes one or more HIV proteins or peptides.

12. The method of claim 11, wherein said HIV protein or peptide is the HIV gag protein or a peptide fragment thereof.

13. The method of claim 11, wherein said nucleic acid introduced encodes both (a) an HIV gag protein or a peptide fragment thereof and (b) an HIV env protein or a peptide fragment thereof.

14. The method of claim 13, wherein said nucleic acid introduced comprises a codon-optimized gag-encoding region and a codon-optimized env-encoding region.

15. The method of claims 1, 2, or 3, wherein said nucleic acid vaccine encoding one or more immunogens of interest is administered to said animal incorporated in a plasmid form.

16. The method of claims 1, 2, or 3, wherein said nucleic acid vaccine encoding one or more immunogens of interest is administered to said animal associated with protein or lipid.

17. The method of claims 1, 2, or 3, wherein said nucleic acid vaccine is introduced to said animal by intramuscular or intradermal injection.

18. The method of claim 3, wherein the first conditions comprise a target site field having a volume in the range from 0.1 cm³ to 5 cm³, a thermal index selected to raise the temperature in the target site by from 10°

C. to 40°

C., and a mechanical index from 0.5 to 20.

19. The method of claim 18, wherein the second conditions comprise a target site field having a volume in the range from 0.01 cm³ to 1 cm³, a thermal index selected to raise the temperature in the target site by from 10°

C. to 40°

C., and a mechanical index in the range from 0.1 to 2.

20. The method of claim 19, wherein the first conditions comprise a field intensity which varies in intensity by less than 6 db in a lateral direction across the width of the field and across the depth of the target site.

21. A system for enhancing an immune response in an animal, said system comprising:

means for administering a nucleic acid vaccine to a target site in tissue in the animal;

means for applying vibrational energy to the target site;

wherein the vibrational energy applying means produces energy which both enhances transfection and which induces an inflammatory response, and

a source of nucleic acid vaccine coupleable to the administering means.

22. A system as in claim 21, wherein the vibrational energy applying means comprises a first transducer which directs vibrational energy at the target site under conditions which enhance transfection of cells in the target site with nucleic acids delivered to the target site by the administering means to produce an antigen encoded by the nucleic acid vaccine.

23. Apparatus as in claim 21, wherein the vibrational energy applying means further comprises a second transducer which directs vibrational energy at the target site under conditions which produce tissue damage to stimulate an immune response to the antigen produced by the transfected cells.

24. A system as in claim 23, further comprising a housing, wherein the first and second transducers are disposed in the housing.

25. A system as in claims 22, 23, or 24, wherein the first transducer operates at a thermal index selected to raise the temperature in the target site by from 10°

C. to 40°

C., and a mechanical index in the range from 0.5 to 20.

26. A system as in claim 25, wherein the second transducer operates at a thermal index selected to raise the temperature in the target site by from 10°

C. to 40°

C., and a mechanical index in the range from 0.1 to 2.

27. A system as in claim 24, wherein the second transducer is arranged annularly about the first transducer and focuses vibrational energy at a region within a beam produced by the first transducer.

28. A system as in claims 21, 22, 23, or 24, wherein the nucleic acid vaccine encodes an immunogen which is a protein or peptide of a pathogen.

29. A system as in claim 28, wherein said pathogen is selected from the group consisting of a bacterium, a fungus, a yeast, a protozoan, and a virus.

30. A system as in claim 29, wherein said pathogen is a bacterium selected from the group consisting of an enteric bacterium, a Clostridium, a Vibrio, a Nocardia, a Corynebacterium, a Listeria, a Legionella, a Bacilli, a Staphylococcus, a Streptococci, a Borrelia, a Mycobacterium, a Neisserium and a Trepanema bacterium.

31. A system as in claim 29, wherein said pathogen is a fungus selected from the group consisting of a Dermatophyte, a Pneumocystis, a Trypanosoma, a Plasmodium, a Candida, a Cryptococcus, a Histoplasma, a Coccidioide, an Amoeba and a Schistosome.

32. A system as in claim 29, wherein said pathogen is a virus selected from the group consisting of a parvovirus, an orthomyxovirus, a paramyxovirus, and picornavirus, a papovirus, a herpesvirus, a togavirus, and a retrovirus.

33. A system as in claim 32, wherein said pathogen is the retrovirus HIV.

34. A system as in claim 33, wherein the DNA administered in step (a) encodes one or more HIV proteins or peptides.

35. A system as in claim 34, wherein said HIV protein or peptide is the HIV gag protein or a peptide fragment thereof.

36. A system as in claim 21, wherein the nucleic acid vaccine encoding said one or more immunogens of interest is incorporated in a plasmid form.

37. A system as in claim 21, wherein the nucleic acid vaccine encoding one or more immunogens of interest is associated with protein or lipid.

38. A system as in claim 21, wherein said means for administering the nucleic acid vaccine to said animal accomplishes intramuscular or intradermal administration of said DNA.

39. A system as in claim 23, wherein said means for administering said DNA is a device selected from the group consisting of a needle and a nucleic acid gun.

40. A system as in claim 39, wherein the applying means comprises a first hand held device which incorporates the first transducer and a second handheld device, separate from the first device, incorporating the second transducer.

41. A system as in claim 39, wherein the applying means comprise a single hand held device incorporating both the first and second transducers, wherein said first and second transducers are arranged such that vibrational energy from the first transducer spans a large volume while vibrational energy from the second transducer is focused within the large volume.

42. A method for enhancing an immune response in an animal, said method comprising:

introducing nucleic acids encoding one or more immunogens to a target site in tissue; and

applying vibrational energy to the target site under at least one set of conditions selected to enhance transfection and to produce an inflammatory response.

43. A system for enhancing an immune response in an animal, said system comprising:

means for administering a nucleic acid vaccine to a target site in tissue in the animal;

means for applying vibrational energy to the target site, wherein the vibrational energy applying means produces energy under a single set of conditions, which both enhances transfection and which induces an inflammatory response; and

a source of nucleic acid vaccine coupleable to the administering means.